Aardvark Therapeutics, Inc. Common Stock (AARD) vs Unicycive Therapeutics, Inc. (UNCY)
A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and Unicycive Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AARD
Aardvark Therapeutics, Inc. Common Stock
$5.04HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UNCY
Unicycive Therapeutics, Inc.
$4.23HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AARD vs UNCY
growth of $100 · dividends reinvested · last 2yAARD -63.5% (-39.6%/yr)UNCY -21.2% (-11.3%/yr)UNCY compounded faster over this window
AARD UNCY
AARD vs UNCY: by the numbers
- •UNCY is the larger company ($113M vs $110M market cap).
Metrics side by side
Valuation
| Metric | AARD | UNCY |
|---|---|---|
| P/B ratio | 1.47 | 2.12 |
Profitability
| Metric | AARD | UNCY |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -93.44% | -66.12% |
| ROIC | -97.99% | -62.15% |
Growth (annualized)
| Metric | AARD | UNCY |
|---|---|---|
| Total return CAGR (5Y) | N/A | -32.14% |
Go deeper
Dig into the metrics
Aardvark Therapeutics, Inc. Common Stock ROEUnicycive Therapeutics ROEAardvark Therapeutics, Inc. Common Stock operating marginUnicycive Therapeutics operating marginAardvark Therapeutics, Inc. Common Stock revenue growthUnicycive Therapeutics revenue growthAardvark Therapeutics, Inc. Common Stock free cash flowUnicycive Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.